



15 September 2026

ASX ANNOUNCEMENT

CONNEQT EGM Presentation

CONNEQT Health Limited (ASX: CQT) (“CONNEQT” or “the Company”) advises that an Extraordinary General Meeting was held today, 15 September 2026.

The presentation slides from the meeting (presented in USD) are attached to this announcement.

A video recording of the presentation will be available on the Company website:

<https://conneqthealth.com/>

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Ben Henri

ben.henri@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health’s mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company’s market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange (“ASX: CQT”).

C O N N E Q T .
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761

“Man is as Old as his arteries” - Thomas Sydenham

**CONNEQT can make
premature heart attacks
a thing of the past**



**Every 2 minutes a
working age
adult experiences
a heart attack**

44
days

away from work




\$35K-\$90K

first-year direct medical costs

Up to

~\$10K


out-of-pocket
exposure



Flexible Artery

50%

reduction in CVD risk



Stiff Artery

2-3X

increase in CVD risk

**2 in 3 adults show
early vascular
aging, yet arterial
health remains
overlooked.**

(Framingham Heart Study)

Arterial health is increasingly treatable

15% to 60% clinical risk reduction across
modern therapeutic classes.

GLP-1s

Proven in SELECT trial

PCSK9 Inhibitors

Proven in FOURIER trial

Inclisiran

Proven in ORION trial

AMGEN

AstraZeneca

Roche

MERCK

novo nordisk®

Lilly

Johnson&Johnson

Boehringer
Ingelheim

Existing tools don't capture aging arteries

SYSTEM VIEW

Patient: Maria, 48

AHA PREVENT calculator

2.1%

LOW RISK

THE HIDDEN REALITY

Actual Biology:

The arteries of an 82-year-old,
premature coronary disease

Reclassified Result:

13.4%

HIGH RISK

A traditional blood-pressure measurement is to the arterial system what a heart-rate measurement is to the electrical system: useful, but incomplete.



**... a 2-minute
assessment can**

By applying advanced algorithms to the familiar blood pressure measurement

Why **home** health Matters

- Visibility & Engagement
- Consumer Acquisition
- Recurring User Revenue
- Brand Reach & Engagement
- Longitudinal Relationship



Why **in-clinic** Matters

- Clinical Credibility
- Distribution & Validation
- Institutional Relationships
- Recurring Account Revenue
- Shared Platform Flywheel




Two Markets, One Platform

- Enterprise builds credibility and strategic leverage.
- Consumer builds reach, retention, and user insight.

See arterial function without requiring imaging

Five biomarkers show how arteries respond to each heartbeat



*CV events are defined as a myocardial infarction, coronary revascularization, stroke, heart failure, or CV mortality

CONNECT Health

A 4-mmHg reduction in central pressure can lower CV risk by 20%. Reductions in arterial stiffness have been shown with ACE-inhibitors, calcium channel blockers, statins, PCSK9 inhibitors, and SGLT2 inhibitors.

**CONNEQT
pioneered
the gold
standard
technology**

SphygmoCor®

Our patented **Pulse Wave Analysis** technology non-invasively extracts functional biomarkers of vascular aging that predicts cardiovascular events.

20+

Years of R&D

3,200+

Peer-Reviewed Studies

Trusted by the World's Best in Healthcare & Science



CONNECT Health



ENTERPRISE

De-risked business ready to scale



CONSUMER

CONSUMER

Yearly Plan
\$199.99

Monthly Plan
\$24.99

10 Pack - **\$99**



ENTERPRISE



Cash pay



Reimbursable
CPT 93050

\$8-15/report

Recurring


One-time



\$289 per unit

\$2,500 setup

Consumer: 0 to ~\$4M run rate in six quarters



*Chart reflects cash receipts at order. GAAP revenue is recognized upon hardware shipment and ratably over the subscription period.

Enterprise: one-time sales into recurring revenue

\$6,100 in year 1, then \$3,600 ARR + overage revenue as utilization grows


Clinic economics	One-time model	Subscription model
Year-one revenue	\$6,500	\$6,100
Base ARR thereafter	—	\$3,600
Usage-based overages	—	Additional upside
Three-year base revenue	\$6,500	\$13,300 + overages
Revenue driver	New equipment sales	New clinics + renewals + utilization



Currently deploying into a 100-location advanced testing franchise

Health spending is moving toward measurement, prevention and longitudinal management

84% of U.S. consumers say wellness is a top or important priority




4–5%

**estimated annual
category growth**

The reported figures are directional lower-bound estimates from separate McKinsey survey years—not a standardized spending series.

ACO performance payments rose 32% year over year



+32%


Medicare Shared Savings Program

Value-based care is putting more economic weight behind prevention, risk identification and longitudinal management.

Calculation: $\$4.1B \div \$3.1B - 1 = 32.3\%$

20% of employers plan to increase well-being investment

2025 Investment Plans




93%
plan to maintain or
increase investment

Survey base: 131 employers

MARKET TAILWIND

DPC and concierge practice sites grew 83% in five years



+83%

U.S. practice sites, 2018–2023

A rapidly expanding premium-primary-care channel creates more potential entry points for routine arterial assessment.

From preventive screening to \$1B recurring revenue

Consumer demand → High-intent entry channel → Population-scale opportunity

Health-conscious
consumers
already pay to
understand risk
earlier

Over 10,000
units sold

Advanced-testing,
concierge and
functional-
medicine practices

Starting with a
**100-location franchise in
41 states**

**Annual screening
for 105 million
working age
Americans
over 40**

Every hidden signal became a category.

Arterial is the last one, and the biggest

Metabolic Health	 LEVELS	US ~\$300M*
Blood Biomarkers	 Function	US \$2.5B*
Performance Fitness	WHOOP®	US \$10B*
Sleep Monitoring	OURA	US \$11B*
ECG Assessments	ALIVECOR®	US ~\$467M*
Arterial Intelligence	CONNECT® Health	Largest unclaimed biomarker category

Whoop and Oura are now adding clinical blood-testing layers, reaching for the validation CONNEQT already owns.

From validated technology to a scalable category

Investment builds the cloud, device, mobile and commercial infrastructure required to make arterial health routinely measured – and recurring revenue.

1 SphygmoCor Cloud

Cloud-native algorithms, data infrastructure, APIs and enterprise interoperability.

Unlocks: biomarker-as-a-service, analytics, third-party integrations and usage revenue.

2 Connected device platform

Pulse Core, XCEL v2, cloud-based biomarker extraction, manufacturing readiness and regulatory execution.

Unlocks: a scalable multi-device ecosystem and faster partner integration.

3 Consumer and clinical experience

Unified mobile workflows for onboarding, measurement, interpretation, reporting and longitudinal engagement.

Unlocks: activation, utilization, retention and overage revenue.

CONNEQT Arterial Health Ecosystem

SphygmoCor® Cloud

Analytics

Data Lake

Algorithm

CONNEQT Pulse



Legacy, doesn't speak cloud and we are exploring how to do so w/o triggering regulatory review.




SphygmoCor XCEL

Pulse + all future devices store data in the Data Lake



CONNEQT V2



XCEL V2

V2+ will do all biomarker extraction in the cloud. No local processing. They also become demonstrator device for 3rd party integration.

TODAY
TOMORROW


Biomarker-as-a-Service (BaaS)

On-demand vascular biomarker extraction for digital health applications


Health Intelligence Marketplace

AI-driven real-world vascular health data for population analytics

Our mobile apps interface between the hardware and cloud components to enable data capture, device orchestration, report delivery, and patient engagement across clinical and consumer environments.



MOBILE



TABLET

Proven operators. Real cardiology. Aligned ownership.



Craig R. Cooper

CEO & Co-Founder

Boost Mobile
Saban Ventures
Softbank Capital Technology Fund
EBT Mobile
NRG Energy



Niall Cairns

Executive Chairman
& Co-Founder

Kestrel Capital
Tambla
Harri
Tru-Test



C2 Ventures

42%



Catherine Liao

Chief Strategy &
Commercial Officer

Blumio
Riverbed
Tradeshift
Cisco
World Health Organization



Oliver Shay

Chief Digital Officer

Blumio
Global Fund
Cisco
World Health Organization



Dr. Sanjeev Bhavnani

Medical Officer – Cardiology

Scripps Clinic
Food and Drug Administration
American College of Cardiology
Anthem AI
Qualcomm Life



Scott Finneran

VP Engineering

Rapid Response Revival
HSBC
Bell Labs Lucent

Thank You



CONNEXIA Health